Aliquots - Research Briefs

A signaling molecule called interleukin-6 may be a therapeutic target to prevent vision loss or nerve degeneration in glaucoma, Vanderbilt researchers have discovered.

Vanderbilt investigators have conducted a first-of-its-kind genome-wide association study of lung cancer survival in African-Americans.

A novel immunotherapy combination induced remarkable regression of tumors in a mouse model of head and neck cancer.

A PET probe that detects the amino acid glutamine predicts whether tumors respond to certain targeted therapies in preclinical animal models.

New findings shed light on how enzymes that replicate DNA skip over mutations that might cause cancer and restart DNA synthesis further away.

Vanderbilt investigators report that dysregulation of certain immune cells in the intestines may lead to inflammation and disease.

Vanderbilt investigators have developed a new method for measuring oxidative stress in human tumors, which provides insight into cancer development.